Didn't Berger say there would be news forthcoming re: the presentation over the weekend (I believe he said this on Friday at the very uneventful conference).
"Based on these data indicating a statistically significant improvement in the trial’s primary endpoint of PFS, Merck has stopped further enrollment in the trial, while continuing to follow surviving patients,” said Eric Rubin, M.D., vice president, Oncology, Merck Research Laboratories.